Related Experiment Video

Updated: Aug 17, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 31, 2013

[Recombinant therapeutic vaccines against cancer of the uterine cervix]

J Berumen1, N Villegas

  • 1Laboratorio Multidisciplinario de Investigación, Escuela Militar de Graduados de Sanidad, Universidad del Ejército y Fuerza Aérea, México.

Salud Publica De Mexico
|July 1, 1997
PubMed

Insights

Cervical cancer evades the immune system by reducing HLA molecules and altering cytokines, impairing T lymphocyte and NK cell responses. Effective anti-tumor immunity requires stimulating both systemic T cell responses and local immune cells within the tumor microenvironment.

Area of Science:

  • Immunology
  • Oncology
  • Virology

Context:

  • Cervical cancer development involves immune evasion mechanisms.
  • Tumoral cells decrease Human Leukocyte Antigen (HLA) class I expression.
  • Tumoral cells secrete specific cytokines that suppress immune responses.

Purpose:

  • To outline the immune evasion strategies employed by cervical cancer.
  • To explain the poor stimulation of cytotoxic T lymphocytes (CTL), helper T lymphocytes (TH), natural killer (NK) cells, and macrophages.
  • To propose requirements for inducing an effective anti-tumor immune response.

Summary:

  • Cervical cancer impedes immune detection through reduced HLA expression and cytokine secretion.
  • This immune suppression limits the activation of key immune cells like CTL, TH, NK cells, and macrophages.
  • Restoring anti-tumor immunity necessitates systemic T cell activation against Human Papilloma Virus (HPV) epitopes and local immune cell stimulation within the tumor.

Impact:

  • Understanding these mechanisms is crucial for developing novel immunotherapies for cervical cancer.
  • Targeting immune evasion pathways could enhance the efficacy of existing treatments.
  • This research highlights the need for combination strategies to overcome tumor-induced immunosuppression.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo07:33

Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo

Published on: September 28, 2022

Related Concept Videos

Recombinant DNA01:09

Recombinant DNA

Overview
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...